Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma

Abstract

Samples were provided by the Biobank of Andalusia (Collection Code: 19150007). The study was approved by the HUVN Ethics and Research Committee, and was conducted according to the Declaration of Helsinki.

Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review

“…The included studies were published between 2013 and 2021 [ 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ]. Most were cohort studies [ 20 , 21 , 22 , 23 , 24 , 26 , 28 , 29 , 30 , 31 ]. Clinical data collection was mainly prospective [ 20 , 21 , 23 , 27 , 28 , 29 , 30 ].…”

“…Clinical data collection was mainly prospective [ 20 , 21 , 23 , 27 , 28 , 29 , 30 ]. Eight studies were conducted in populations of European ancestry [ 20 , 21 , 23 , 24 , 25 , 26 , 29 , 31 ], two in the Indian population [ 28 , 30 ], and one in patients of Asian origin [ 32 ]. In two studies, the ethnicity of the study population was not specified [ 22 , 27 ].…”

“…In two studies, the ethnicity of the study population was not specified [ 22 , 27 ]. Regarding the treatment regimens studied, five studies evaluated patients under treatment with capecitabine in combination with other neoplastic agents [ 23 , 24 , 28 , 29 , 30 ], three with capecitabine as monotherapy [ 20 , 27 , 31 ], and five with capecitabine as monotherapy and in combination [ 21 , 22 , 25 , 26 , 32 ]. Five studies only investigated capecitabine PD-related genes [ 20 , 24 , 27 , 29 , 32 ], two only investigated PK-related genes [ 23 , 28 ], and six studied genes related to both [ 21 , 22 , 25 , 26 , 30 , 31 ].…”

“…Regarding the treatment regimens studied, five studies evaluated patients under treatment with capecitabine in combination with other neoplastic agents [ 23 , 24 , 28 , 29 , 30 ], three with capecitabine as monotherapy [ 20 , 27 , 31 ], and five with capecitabine as monotherapy and in combination [ 21 , 22 , 25 , 26 , 32 ]. Five studies only investigated capecitabine PD-related genes [ 20 , 24 , 27 , 29 , 32 ], two only investigated PK-related genes [ 23 , 28 ], and six studied genes related to both [ 21 , 22 , 25 , 26 , 30 , 31 ]. Eight studies evaluated the influence of SNPs on the incidence and severity of capecitabine-induced toxicity [ 21 , 22 , 23 , 25 , 26 , 28 , 31 , 32 ], three assessed the influence of SNPs on the effectiveness of capecitabine-based therapy [ 24 , 27 , 30 ], and two evaluate the influence of SNPs on both toxicity and effectiveness [ 20 , 29 ].…”

The Association Between the XRCC1 Arg399Gln Polymorphism and the Risk of Head and Neck Cancer: An Updated Meta-Analysis Including 14586 Subjects

“…XRCC1, an important component of basilectomy repair system, plays a key role in protecting cells from DNA damage and maintaining genomic integrity. In recent years, many studies have shown that common genetic polymorphisms in XRCC1 gene are significant correlated with development and procession of cancer, such as colorectal carcinoma, 42 lung cancer, 43 breast cancer 44 and HNC. Since 1999, accumulated evidence has identified specific associations between XRCC1 polymorphisms and an increased risk of HNC.…”